Decreased serum orexin A levels in drug-naive children with attention deficit and hyperactivity disorder

  • Saliha Baykal
  • Yakup Albayrak
  • Ferit Durankuş
  • Savaş Güzel
  • Özlem Abbak
  • Nihan Potas
  • Murat Beyazyüz
  • Koray Karabekiroğlu
  • Mustafa Metin Donma
Original Article


Attention deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric disorders of childhood and characterized by inattention, hyperactivity, and impulsivity. ADHD is a neurodevelopmental disorder, and its etiology has not yet been determined precisely. Orexin A is thought to play an important role in different forms of learning, memory, and attention. Despite its importance in attention and learning, no study has investigated serum orexin levels in patients with ADHD. In the present study, we aimed to compare serum orexigenic neuropeptides such as orexin A and orexin B, neuropeptide Y, and ghrelin between drug naive children with ADHD and healthy children. Fifty-six drug-naive children with ADHD and 40 healthy controls were enrolled in the study. After comparison of serum orexin A and orexin B, neuropeptide Y, and ghrelin, we found that serum orexin A levels were significantly lower in the ADHD group (p = 0.001). Furthermore, serum orexin A levels were compared between ADHD subgroups. Orexin A levels were significantly lower in the inattentive subtype compared with the hyperactive subtype and combined subtype (p = 0.009). Our results indicate that orexin A might be a neurobiological etiological factor in ADHD, particularly associated with attention symptoms. The present study is the first to demonstrate decreased serum orexin A levels in drug-naive children with ADHD. Further studies are needed to confirm our results and to show the effects of treatments involving orexin A in patients with ADHD.


Orexin Attention Hyperactivity Etiology Neurobiology 



The present study was supported by Tekirdağ Namık Kemal University Scientific Research Community (Grant Number: NKUBAP.02.GA.17.09)

Compliance with ethical standards

The present study was approved by the Namık Kemal University Non-Invasive Clinic Research Ethical Committee.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (5th ed). American Psychiatric Publishing, ArlingtonGoogle Scholar
  2. 2.
    Rohani M, Fasano A, Lang AE, Zamani B, Javanparast L, Bidgoli MR, Alavi A (2018) Pantothenate kinase-associated neurodegeneration mimicking Tourette syndrome: a case report and review of the literature. Neurol Sci 39:1797–1800. CrossRefGoogle Scholar
  3. 3.
    Pliszka SR (2015) Conceptual issues in understanding comorbidity in ADHD. In: Adler LA, Spencer TJ, Wilens TE (eds) Attention-deficit hyperactivity disorder in adults and children, 1st edn. Cambridge University Press, UK, pp 63–72CrossRefGoogle Scholar
  4. 4.
    Tripp G, Wickens JR (2009) Neurobiology of ADHD. Neuropharmacology 57(7–8):579–589CrossRefGoogle Scholar
  5. 5.
    Caye A, Swanson JM, Coghill D, Rohde LA (2018) Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol Psychiatry.
  6. 6.
    Quarta D, Smolders I (2014) Rewarding, reinforcing and incentive salient events involve orexigenic hypothalamic neuropeptides regulating mesolimbic dopaminergic neurotransmission. Eur J Pharm Sci 57:2–10CrossRefGoogle Scholar
  7. 7.
    Kastin AJ, Akerstrom V (1999) Nonsaturable entry of neuropeptide Y into brain. Am J Phys:E479–E482Google Scholar
  8. 8.
    De la Herrán-Arita AK, Guerra-Crespo M, Drucker-Colín R (2011) Narcolepsy and orexins: an example of progress in sleep research. Front Neurol 2:26PubMedPubMedCentralGoogle Scholar
  9. 9.
    Uriarte M, De Francesco PN, Fernandez G, Cabral A, Castrogiovanni D, Lalonde T, Luyt LG, Trejo S, Perello M (2018) Evidence supporting a role for the blood-cerebrospinal fluid barrier transporting circulating ghrelin into the brain. Mol Neurobiol.
  10. 10.
    Cortese S, Konofal E, Lecendreux M (2008) Alertness and feeding behaviors in ADHD: does the hypocretin/orexin system play a role? Med Hypotheses 71(5):770–775CrossRefGoogle Scholar
  11. 11.
    Li SB, Jones JR, de Lecea L (2016) Hypocretins, neural systems, physiology, and psychiatric disorders. Curr Psychiatry Rep 18(1):7CrossRefGoogle Scholar
  12. 12.
    Faraone SV (2018) The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev 87:255–270CrossRefGoogle Scholar
  13. 13.
    Achenbach TM, Edelbrock C (1983) Manual for the child behavior checklist and revised child behavior profile. Queen City Printers, BurlingtonGoogle Scholar
  14. 14.
    Kaufman J, Birmaher B, Brent D (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (KSADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988CrossRefGoogle Scholar
  15. 15.
    Matthews M, Nigg JT, Fair DA (2014) Attention deficit hyperactivity disorder. Curr Top Behav Neurosci 16:235–266CrossRefGoogle Scholar
  16. 16.
    Cook EH Jr, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL (1995) Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56:993–998PubMedPubMedCentralGoogle Scholar
  17. 17.
    Madras BK, Miller GM, Fischman AJ (2005) The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1397–1409CrossRefGoogle Scholar
  18. 18.
    VanNess SH, Owens MJ, Kilts CD (2005) The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 6(55):55CrossRefGoogle Scholar
  19. 19.
    Borodovitsyna O, Flamini M, Chandler D (2017) Noradrenergic modulation of cognition in health and disease. Neural Plast 2017:6031478Google Scholar
  20. 20.
    Zajo KN, Fadel JR, Burk JA (2016) Orexin A-induced enhancement of attentional processing in rats: role of basal forebrain neurons. Psychopharmacology 233(4):639–647CrossRefGoogle Scholar
  21. 21.
    Mahler SV, Smith RJ, Moorman DE, Sartor GC, Aston-Jones G (2012) Multiple roles for orexin/hypocretin in addiction. Prog Brain Res 198:79–121CrossRefGoogle Scholar
  22. 22.
    Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JRS, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573–585CrossRefGoogle Scholar
  23. 23.
    Ritchie C, Okuro M, Kanbayashi T, Nishino S (2010) Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights. Curr Neurol Neurosci Rep 10:180–189CrossRefGoogle Scholar
  24. 24.
    Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27:469–474CrossRefGoogle Scholar
  25. 25.
    Arrigoni E, Mochizuki T, Scammell TE (2010) Activation of the basal forebrain by the orexin/hypocretin neurones. Acta Physiol (Oxf) 198:223–235CrossRefGoogle Scholar
  26. 26.
    Fadel J, Burk JA (2010) Orexin/hypocretin modulation of the basal forebrain cholinergic system: role in attention. Brain Res 1314:112–123CrossRefGoogle Scholar
  27. 27.
    Boschen KE, Fadel JR, Burk JA (2009) Systemic and intrabasalis administration of the orexin-1 receptor antagonist, SB-334867, disrupts attentional performance in rats. Psychopharmacology (Berlin) 206:205–213CrossRefGoogle Scholar
  28. 28.
    Fadel J, Jolivalt CG, Reagan LP (2013) Food for thought: the role of appetitive peptides in age-related cognitive decline. Ageing Res Rev 12:764–776CrossRefGoogle Scholar
  29. 29.
    Fronczek R, van Geest S, Frolich M, Overeem S, Roelandse FW, Lammers GJ, Swaab DF (2012) Hypocretin (orexin) loss in Alzheimer’s disease. Neurobiol Aging 33:1642–1650CrossRefGoogle Scholar
  30. 30.
    Slats D, Claassen JA, Lammers GJ, Melis RJ, Verbeek MM, Overseem S (2012) Association between hypocretin-1 and amyloid-β42 cerebrospinal fluid levels in Alzheimer’s disease and healthy controls. Curr Alzheimer Res 9:1119–1125CrossRefGoogle Scholar
  31. 31.
    Wennstrom M, Londos E, Minthon L, Nielsen HM (2012) Altered CSF orexin and α-synuclein levels in dementia patients. J Alzheimers Dis 29:125–132CrossRefGoogle Scholar
  32. 32.
    Deadwyler SA, Porrino L, Siegel JM, Hampson RE (2007) Systemic and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 27:14239–14247CrossRefGoogle Scholar
  33. 33.
    Akbari E, Naghdi N, Motamedi F (2007) The selective orexin 1 receptor antagonist SB-334867-A impairs acquisition and consolidation but not retrieval of spatial memory in Morris water maze. Peptides 28:650–656CrossRefGoogle Scholar
  34. 34.
    Aou S, Li XL, Li AJ, Oomura Y, Shiraishi T, Sasaki K, Imamura T, Wayner MJ (2003) Orexin-A (hypocretin-1) impairs Morris water maze performance and CA1-Schaffer collateral long-term potentiation in rats. Neuroscience 119:1221–1228CrossRefGoogle Scholar
  35. 35.
    Jaeger LB, Farr SB, Banks WA, Morley JE (2002) Effects of orexin-A on memory processing. Peptides 23:1683–1688CrossRefGoogle Scholar
  36. 36.
    Yang L, Zou B, Xiong X, Pascual C, Xie J, Malik A, Xie J, Sakurai T, Xie XS (2013) Hypocretin/orexin neurons contribute to hippocampus dependent social memory and synaptic plasticity in mice. J Neurosci 33:5275–5284CrossRefGoogle Scholar
  37. 37.
    Lundberg JM, Terenius L, Hokfelt T et al (1982) Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effect of NPY on sympathetic function. Acta Physiol Scand 116:477–480CrossRefGoogle Scholar
  38. 38.
    Hashimoto K (2010) Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatr Clin Neurosci 64:341–357CrossRefGoogle Scholar
  39. 39.
    Lindell SG, Schwandt ML, Sun H, Sparenborg JD, Björk K, Kasckow JW, Sommer WH, Goldman D, Higley JD, Suomi SJ, Heilig M, Barr CS (2010) Functional NPY variation as a factor in stress resilience and alcohol consumption in rhesus macaques. Arch Gen Psychiatry 67:423–431CrossRefGoogle Scholar
  40. 40.
    Zhu G, Pollak L, Mottagui-Tabar S, Wahlestedt C, Taubman J, Virkkunen M, Goldman D, Heilig M (2003) NPY Leu7Pro and alcohol dependence in Finnish and Swedish populations. Alcohol Clin Exp Res 27:19–24CrossRefGoogle Scholar
  41. 41.
    Heilig M, Zachrisson O, Thorsell A, Ehnvall A, Mottagui-Tabar S, Sjögren M, Åsberg M, Ekman R, Wahlestedt C, Ågren H (2004) Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res 38:113–121CrossRefGoogle Scholar
  42. 42.
    Oades RD, Daniels R, Rascher W (1998) Plasma neuropeptide-Y levels, monoamine metabolism, electrolyte excretion and drinking behavior in children with attention-deficit hyperactivity disorder. Psychiatry Res 80:177–186CrossRefGoogle Scholar
  43. 43.
    Özcan Ö, Arslan M, Güngör S, Yüksel T, Selimoğlu MA (2018) Plasma leptin, adiponectin, neuropeptide Y levels in drug naive children with ADHD. J Atten Disord 22(9):896–900CrossRefGoogle Scholar
  44. 44.
    Hekim Bozkurt Ö, Güney E, Göker Z, Şenses Dinç G, Alışık M, Erel Ö, Çöp E, Üneri ÖŞ (2018) Neuropeptide Y levels in children and adolescents with attention deficit hyperactivity disorder. Turk Psikiyatri Derg 29(1):31–35PubMedGoogle Scholar
  45. 45.
    Colldén G, Tschöp MH, Müller TD (2017) Therapeutic potential of targeting the ghrelin pathway. Int J Mol Sci 18(4):E798Google Scholar
  46. 46.
    Gurbuz F, Gurbuz BB, Celik GG, Yildirim V, Ucakturk SA, Seydaoglu G, Ucakturk EM, Topaloglu AK, Yuksel B (2016) Effects of methylphenidate on appetite and growth in children diagnosed with attention deficit and hyperactivity disorder. Pediatr Endocrinol Metab 29(1):85–92Google Scholar
  47. 47.
    Sahin S, Yuce M, Alacam H, Karabekiroglu K, Say GN, Salıs O (2014) Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder. Int J Psychiatry Clin Pract 18(4):280–287CrossRefGoogle Scholar
  48. 48.
    Pakdaman F, Irani F, Tajikzadeh F, Jabalkandi SA (2018) The efficacy of Ritalin in ADHD children under neurofeedback training. Neurol Sci 39:2071–2078. CrossRefPubMedGoogle Scholar

Copyright information

© Fondazione Società Italiana di Neurologia 2019

Authors and Affiliations

  1. 1.Faculty of Medicine, Department of Child and Adolescent PsychiatryTekirdağ Namık Kemal UniversityTekirdagTurkey
  2. 2.Faculty of Medicine, Department of PsychiatryTekirdağ Namık Kemal UniversityTekirdagTurkey
  3. 3.Faculty of Medicine, Department of PediatricsOkan UniversityIstanbulTurkey
  4. 4.Faculty of Medicine, Department of BiochemistryTekirdağ Namık Kemal UniversityTekirdagTurkey
  5. 5.Faculty of Economics and Administrative Science, Department of Healthcare ManagementGazi UniversityAnkaraTurkey
  6. 6.Faculty of Medicine, Department of Child and Adolescent PsychiatryOndokuz Mayıs UniversitySamsunTurkey
  7. 7.Faculty of Medicine, Department of PediatricsTekirdağ Namık Kemal UniversityTekirdagTurkey

Personalised recommendations